Strength determines confidence
Release time:
2020-08-14
Strength Determines Strength
Life is a balance beam. When you are weak, all difficulties will tilt towards you. When you are constantly strong and have skills, you will have strength and confidence to keep your life balanced.
I have participated in many symposiums organized by the company, at which I talked about the development of enterprises and personal development. The development of enterprises and personal development, the two are complementary. The development of an enterprise depends on the quality and efficiency of its products. Where does quality come from, by research and development, by production. The R & D and production front-line personnel are involved in the whole process. If individuals want to develop, they must constantly improve their professional skills, be familiar with product technology, integrate themselves into the team, and create greater value. This value, can promote the enterprise to get better development, then, this is the strength of the enterprise. As a wholly-owned subsidiary of Jianfeng Group,
Jianfeng Pharmaceutical Co., Ltd. adopted the strategic mode of "grasping both ends (products and sales) and promoting the middle ( production ) " from the beginning of acquisition, merger and equity participation to the formal registration and establishment of 1998 12 , focus on innovation, from the drug research and development link to grasp the quality. Nowadays, the direction of research and development has shifted from antidepressants, antibiotics, and cardiovascular and cerebrovascular drugs to anti-tumor preparations, Junior College drugs, and children's drugs, and has launched a number of key products, occupying a dominant position in the market. 2007 August April 31 approved the listing of penciclovir for injection. After more than 8 years, the company invested more than 1000 yuan, leading some European and American countries and becoming the exclusive new drug listed in the world. At present, the company is actively carrying out new drug research and development, the injection of deoxygenated podophyllotoxin has been approved by the State Administration of Drug Administration for clinical trials, is expected to complete clinical trials and declare production in 2021 . Deoxypodophyllotoxin as a new class of cytotoxic anti-tumor drugs, compared with similar antineoplastic drugs, has a high efficiency, broad-spectrum anti-tumor activity, the drug-resistant tumor strains and sensitive tumor strains are equally effective, while the impact on the heart, liver and bone marrow is smaller. This product has won many patents since it was developed in 2010 . If the clinical trial is successful, it can replace the similar anti-tumor drugs that have been listed in China and become the first-line drug in the market and the first product of the global patent. The emergence of such new drugs is bound to fill the gaps in the market for similar drugs and increase the company's market competitiveness.
Analyzes the current general environment of the pharmaceutical industry. In 2017 , the state vigorously implemented the medical reform policy, further implemented the "two-vote system" and "graded diagnosis and treatment", controlled the proportion of drugs in hospitals, and put pressure on product sales after implementing "standardized drug use". The implementation of bidding mechanisms in different places has also made it difficult for non-medical insurance products to enter hospitals, the survival of the non-exclusive product market is worrying. In order to better solve these problems, in addition to changing the sales model and price strategy, we should also return to the R & D and production of products, and strive to control the standard operation of raw materials, production technology and equipment. Then the quality of products and the new drugs developed will become the strength of enterprises. With this strength to impact the market, sales will have more confidence.
Strength is the power of real talent and learning. Whether at work or in life, our confidence is the most important and basic thing that comes from our own strength. Therefore, only when you become stronger can you have the courage and perseverance to impact the broader overseas market after standing firm in the local market. (Lang Minxiao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page